Monopar Therapeutics
MNPR
8 hedge funds and large institutions have $165K invested in Monopar Therapeutics in 2023 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 5 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
0.06% less ownership
Funds ownership: 0.35% → 0.29% (-0.06%)
27% less funds holding
Funds holding: 11 → 8 (-3)
49% less capital invested
Capital invested by funds: $323K → $165K (-$158K)
60% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$33.5K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
+$3.09K |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$153 |
| 4 |
Wells Fargo
San Francisco,
California
|
+$5 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Northern Trust
Chicago,
Illinois
|
-$51.5K |
| 2 |
KPWS
Kestra Private Wealth Services
Austin,
Texas
|
-$32.6K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$8.88K |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$7K |
| 5 |
JP Morgan Chase
New York
|
-$3K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
1
Vanguard Group
Malvern,
Pennsylvania
| $84.8K | -$818 | -160 | -0.8% |
|
2
Geode Capital Management
Boston,
Massachusetts
| $35.8K | – | – | – |
|
|
3
Millennium Management
New York
| $28K | +$33.5K | +6,552 | New |
|
|
RRCM
4
Rappaport Reiches Capital Management
Skokie`,
Illinois
| $9.14K | – | – | – |
|
5
Morgan Stanley
New York
| $3.42K | – | – | – |
|
|
TRCT
6
Tower Research Capital (TRC)
New York
| $3.19K | +$3.09K | +604 | +422% |
|
|
7
Fidelity Investments
Boston,
Massachusetts
| $128 | +$153 | +30 | New |
|
|
8
Wells Fargo
San Francisco,
California
| $28 | +$5 | +1 | +17% |
|
|
9
Northern Trust
Chicago,
Illinois
| – | -$51.5K | -7,410 | Closed |
|
|
KPWS
10
Kestra Private Wealth Services
Austin,
Texas
| – | -$32.6K | -4,691 | Closed |
|
|
11
UBS Group
Zurich,
Switzerland
| – | -$8.88K | -1,278 | Closed |
|
|
12
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$7K | -1,000 | Closed |
|
|
13
JP Morgan Chase
New York
| – | -$3K | -483 | Closed |
|
MNPR Hedge Fund Activity: Q2 2023 in Review
8 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Monopar Therapeutics (MNPR) for Q2 2023, worth a combined $165K — down 49% from $323K a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of MNPR and 2 opened new positions — a net loss of 3 holders — while 1 trimmed existing stakes and 2 added.
The largest buyer was Millennium Management, opening a new position worth an estimated $33.5K. The largest seller was Northern Trust, exiting entirely with an estimated $51.5K sold.
- 8 institutional investors held Monopar Therapeutics (MNPR) as of Q2 2023, down from 11 in Q1 2023.
- Funds reported $165K of Monopar Therapeutics stock for Q2 2023, down 49% quarter-over-quarter.
- 2 funds opened new Monopar Therapeutics positions in Q2 2023 and 5 closed out, a net change of -3 holders.
- The largest Monopar Therapeutics buyer in Q2 2023 was Millennium Management, an estimated $33.5K added.
- The largest Monopar Therapeutics seller in Q2 2023 was Northern Trust, an estimated $51.5K sold.
Based on aggregated 13F filings for Q2 2023.